Prognostic Importance of the Soluble Form of IL-2 Receptor^|^alpha; (sIL-2R^|^alpha;) and its Relationship with Surface Expression of IL-2R^|^alpha; (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases
-
- Hashimoto Yoko
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine Department of Blood Transfusion Service, Gunma University Hospital
-
- Yokohama Akihiko
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine Department of Blood Transfusion Service, Gunma University Hospital
-
- Saitoh Akio
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Nakahashi Hirotaka
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Toyama Kohtaro
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Mitsui Takeki
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Koiso Hiromi
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Saitoh Takayuki
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Handa Hiroshi
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Uchiumi Hideki
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Jinbo Takahiro
- Internal Medicine, Fujioka General Hospital
-
- Murayama Kayoko
- Department of Hematology, Gunma Prefectural Cancer Center
-
- Matsumoto Morio
- Department of Hematology, National Hospital Organization Nishigunma National Hospital
-
- Sawamura Morio
- Department of Hematology, National Hospital Organization Nishigunma National Hospital
-
- Karasawa Masamitsu
- Department of Blood Transfusion Service, Gunma University Hospital
-
- Murakami Hirokazu
- School of Health Sciences, Gunma University Graduate School of Medicine
-
- Hirato Junko
- Clinical Department of Pathology, Gunma University Hospital
-
- Nojima Yoshihisa
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
-
- Kojima Masaru
- Anatomic and Diagnostic Pathology, Dokkyo University School of Medicine
-
- Tsukamoto Norifumi
- Department of Medicine and Clinical Science, Gunma University Graduate School of Medicine
書誌事項
- タイトル別名
-
- Prognostic Importance of the Soluble Form of IL-2 Receptorα (sIL-2Rα) and its Relationship with Surface Expression of IL-2Rα (CD25) of Lymphoma Cells in Diffuse Large B-cell Lymphoma Treated with CHOP-like Regimen with or without Rituximab : A Retrospective Analysis of 338 Cases
この論文をさがす
抄録
We evaluated the prognostic significance of the serum level of the soluble form of interleukin-2 receptorα (sIL-2Rα) and investigated its association with CD25 expression on tumor cells in diffuse large B-cell lymphoma (DLBCL). Three hundred and thirty-eight adult patients with newly diagnosed DLBCL were eligible for this retrospective study. 32.2% of patients were treated with CHOP-like regimen and 67.8% with R-CHOP-like regimen. CD25 expression on the surface of tumor cells was evaluated in 143 cases and its relationship with sIL-2Rα level was also investigated. Both overall survival (OS) and progression-free survival (PFS) were poorer in patients with higher sIL-2Rα, in both R-CHOP and CHOP groups. sIL-2Rα > 1,000 U/mL and performance status (PS) ≥ 2 were independently associated with poorer OS, and sIL-2Rα > 1,000 U/mL, age > 60 years, and ≥ 2 extranodal sites were independently associated with poorer PFS in the R-CHOP group. The sIL-2Rα level was higher in the CD25-positive group than in the CD25-negative group in stage 3 or 4 disease (p = 0.010). Multiple linear regression analysis showed CD25 expression to be independently correlated with sIL-2Rα levels. High sIL-2Rα is an important risk factor for survival in DLBCL treated with not only CHOP-like, but also R-CHOP-like regimens, regardless of the tumor's expression of CD25. [J Clin Exp Hematop 53(3) : 197-205, 2013]
収録刊行物
-
- Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ ａｎｄ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ
-
Ｊｏｕｒｎａｌ ｏｆ Ｃｌｉｎｉｃａｌ ａｎｄ Ｅｘｐｅｒｉｍｅｎｔａｌ Ｈｅｍａｔｏｐａｔｈｏｌｏｇｙ 53 (3), 197-205, 2013
日本リンパ網内系学会